Crossmark

Authors

Cooper Blenkinsopp, Selin

Fu, Qinggong

Green, Yulia

Madan, Anuradha

Juliao, Patricia https://orcid.org/0000-0001-6241-483X

Goldman, Daniel W

Roth, David A

Petri, Michelle A https://orcid.org/0000-0003-1441-5373

Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01639339 at ClinicalTrials.gov

Documents that mention this clinical trial

POS0529 OBINUTUZUMAB BENEFITS PATIENTS WITH ACTIVE LUPUS NEPHRITIS IRRESPECTIVE OF BASELINE PROTEINURIA SEVERITY: A POST HOC ANALYSIS OF THE PHASE II NOBILITY TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.1543

Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort
https://doi.org/10.1136/lupus-2024-001264

PO:11:297 Kidney function preservation with belimumab in patients with lupus nephritis receiving MMF standard therapy in BLISS-LN: improved proteinuria, clinical outcomes and biomarkers for belimumab vs placebo
https://doi.org/10.1136/lupus-2026-el.350

POS0689 A 6-MONTH OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1583

1104 Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN)
https://doi.org/10.1136/lupus-2022-lupus21century.69

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
https://doi.org/10.1136/annrheumdis-2020-217101

PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.125

OP0164 BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.3881

Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort
https://doi.org/10.1136/lupus-2021-000598

PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.129

MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
https://doi.org/10.1136/lupus-2022-000746

506 Belimumab (BEL) improves renal outcomes in active Lupus Nephritis (LN): a phase 3 randomized, Placebo (PBO)-controlled trial
https://doi.org/10.1136/lupus-2021-lupus21century.24

Effect of belimumab on patients with lupus nephritis and impaired kidney function: post hoc subgroup analysis of the phase III BLISS-LN trial
https://doi.org/10.1136/lupus-2025-001834

Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505

PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification
https://doi.org/10.1136/lupus-2022-elm2022.126

Dialogue: A blissful future for lupus nephritis: harnessing repeat kidney biopsies to identify meaningful biomarkers of disease
https://doi.org/10.1136/lupus-2015-000083

Safety and Efficacy of Belimumab in Patients with Lupus Nephritis
https://doi.org/10.2215/cjn.02520322